Form 4: Health In Tech CSO Granted Performance-Based Stock

Health In Tech's Chief Strategy Officer, Jonathan Del Lockett, was granted 7,000 restricted shares of Class A Common Stock, tied to the successful launch of two key company programs.

Summary

• Jonathan Del Lockett, Chief Strategy Officer of Health In Tech, Inc. (HIT), acquired 7,000 shares of Class A Common Stock on August 15, 2025.
• These shares are restricted stock granted under the Health in Tech Equity Incentive Plan at a price of $0 per share.
• The vesting of 50% of these shares is contingent on the successful launch and operational status of the first specified company program, vesting in equal monthly installments over a twelve-month period thereafter.
• The remaining 50% of the shares will vest under the same conditions upon the successful launch and operational status of the second specified company program.
• Following this transaction, Jonathan Del Lockett beneficially owns 93,539 shares of Class A Common Stock, comprising 71,434 common shares and 22,105 restricted shares.
• He also holds 165,085 options to purchase Class A Common Stock, which are not included in the reported beneficial ownership count.

Sentiment

Score: 7

Explanation: The grant of performance-based restricted stock to a key executive is generally positive as it aligns management incentives with the company's strategic objectives and future program launches. However, the vesting is contingent on future program success, introducing a degree of uncertainty.

Positives

• The grant of performance-based restricted stock aligns the Chief Strategy Officer's incentives directly with the successful execution of key company programs, fostering long-term value creation.
• Increases the Chief Strategy Officer's beneficial ownership in the company, demonstrating a commitment to its future success.

Negatives

• The vesting of the 7,000 restricted shares is entirely contingent on the future successful launch and operational status of two unspecified programs, introducing execution risk and uncertainty regarding the actual realization of the compensation.

Risks

• Vesting of 7,000 restricted shares is contingent on the successful launch and operational status of two specified company programs, introducing significant execution risk related to product development and market entry.
• Failure to successfully launch and make operational these programs could result in the forfeiture of the restricted shares, impacting executive compensation and potentially signaling operational challenges.

Future Outlook

The vesting conditions for the restricted shares indicate a strategic focus on the future successful launch and operationalization of two specific company programs, signaling anticipated product development milestones and market entry efforts.

Management Comments

• Fifty percent of the restricted stock will vest over a twelve-month period commencing on the date that the first of two specified programs is successfully launched and fully operational in the marketplace.
• The remaining fifty percent of the restricted stock will vest over a twelve-month period commencing on the date that the other specified program is successfully launched and fully operational in the marketplace.

Industry Context

Granting performance-based restricted stock is a common practice in the technology and healthcare sectors to incentivize executive performance and align management interests with long-term strategic goals, particularly for companies focused on achieving specific product development and market penetration milestones.

Stakeholder Impact

• Shareholders: Potential for increased long-term value if the company's strategic programs are successfully launched, as executive incentives are directly aligned with these outcomes.
• Management/Executives: Provides a direct financial incentive for the Chief Strategy Officer to achieve the successful launch and operationalization of key company programs.

Next Steps

• Successful launch and operationalization of two specified company programs, which will trigger the vesting of the restricted shares.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant tied to future performance milestones. While positive for incentive alignment, it does not provide new information significant enough to warrant a change in investment recommendation. Investors should continue to monitor the progress of the company's strategic programs.

Keywords

Health In Tech, HIT, SEC Form 4, Restricted Stock, Equity Incentive Plan, Executive Compensation, Jonathan Del Lockett, Chief Strategy Officer, Stock Grant, Performance Vesting